Shanghai Hengrui Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Medicine Co., Ltd, has licensed Scilligence ELN (Electronic Laboratory Notebook) as a company-wide platform for their drug discovery and development effort. This State-of-the-art ELN platform will empower more efficient collaborations and knowledge management within the company and with external collaborators including CROs.

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

About Shanghai Hengrui Pharmaceutical Co., Ltd
Shanghai Hengrui Pharmaceutical Co. Ltd. is the research and development Center of Jiangsu Hengrui Medicine Co., Ltd., which is a fully integrated pharmaceutical company in China, with annual net sales of over U.S. $1.4 billion. Hengrui is recognized as the top innovative Chinese drug company, with about 20 new molecular entities entering clinical trials and dozens more under pre-clinical development. Hengrui’s products and R&D span over multiple therapeutic areas, such as oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media, and anti-inflammation. Please visit http://www.shhrp.com and http://www.hrs.com.cn for further information.

Shanghai Syn-The-All Pharmaceutical Co. Ltd. (STA), a subsidiary of WuXi AppTec, has licensed Scilligence ELN (Electronic Laboratory Notebook) as a company-wide platform. This is yet another major collaboration since WuXi AppTec’s Chemistry Service Unit first implemented Scilligence ELN more than 3 years ago.

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.” Please visit www.wuxiapptec.com for more information about WuXi AppTec.

About STA
Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), a WuXi AppTec company, is a leading small molecule process development and manufacturing capability and technology platform company serving the life science industry, with operations in China and the United States. As a premier Contract Development and Manufacturing Organization (CDMO), STA offers our worldwide partners efficient, flexible and high-quality solutions for small molecule Active Pharmaceutical Ingredients (APIs) and advanced intermediates from preclinical to commercial. For more information, please visit www.STApharma.com

If you are in the pharma and biotech industry, you have probably heard of the up and coming startup that provides scientists and researchers with integrated informatics platforms that facilitate collaboration and address knowledge, project, workflow and material management. Scilligence has seen some impressive growth since its start in 2010 with wide adoption of its informatics solutions by pharma, biotech, and chemical companies; government agencies; research institutes; hospitals; and universities. After experiencing ample expansion, Scilligence decided it was time to revamp their brand and logo.

The Scilligence name, is a combination of the words “Science” and “Intelligence”. The new logo needed to capture these two aspects so you could see them as separate entities but also working together. The new logo (right) is much more modern and less mechanical than the old one (left). The color palette was chosen to display Scilligence’s creative, collaborative side (yellow) and its sophisticated, intellectual side (purple). The lightbulb image contains a DNA helix and a small molecule to signify Scilligence’s biggest accomplishment: the first to develop informatics platform that bridged small molecules and biologics. The logo and new brand showcase what differentiates Scilligence from its competitors and the bright future ahead for the company.

To learn more about Scilligence please visit the newly designed and user-friendly site: www.scilligence.com. Scilligence is currently offering TouchMol4Office (Microsoft Office add-in that enables cheminformatics and bioinformatics) free for academia!